ATE485056T1 - Verbesserte impfstoffe - Google Patents

Verbesserte impfstoffe

Info

Publication number: ATE485056T1
Authority: AT; Austria
Prior art keywords: improved vaccines; pathogens; xzxz; xzx; immunostimulatory
Prior art date: 2003-03-24

Application number

AT04722281T

Other languages

English (en)

Inventor

Michael Buschle

Andre Habel

Joerg Fritz

Karin Prinz

Karen Lingnau

Original Assignee

Intercell Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-24

Filing date

2004-03-22

Publication date

2010-11-15

2004-03-22 Application filed by Intercell Ag filed Critical Intercell Ag

2010-11-15 Application granted granted Critical

2010-11-15 Publication of ATE485056T1 publication Critical patent/ATE485056T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 2
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 abstract 1
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
244000052769 pathogen Species 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
244000052613 viral pathogen Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04722281T 2003-03-24 2004-03-22 Verbesserte impfstoffe ATE485056T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP03450072		2003-03-24
EP03450084		2003-04-11
EP03450171		2003-07-11
PCT/EP2004/003002 WO2004084938A1 (en)	2003-03-24	2004-03-22	Improved vaccines

Publications (1)

Publication Number	Publication Date
ATE485056T1 true ATE485056T1 (de)	2010-11-15

Family

ID=33101777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04722281T ATE485056T1 (de)	2003-03-24	2004-03-22	Verbesserte impfstoffe

Country Status (9)

Country	Link
US (3)	US7704514B2 (de)
EP (2)	EP1608402B1 (de)
JP (3)	JP4676426B2 (de)
AT (1)	ATE485056T1 (de)
AU (2)	AU2004224746B2 (de)
CA (1)	CA2517673C (de)
DE (1)	DE602004029657D1 (de)
ES (1)	ES2562456T3 (de)
WO (1)	WO2004084938A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001281812B2 (en) *	2000-06-08	2005-04-07	Valneva Austria Gmbh	Immunostimulatory oligodeoxynucleotides
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
DE10144906B4 (de)	2001-09-12	2013-11-28	Novartis Vaccines And Diagnostics Gmbh	Verfahren zur großtechnischen Herstellung von Impfstoffen
JP2005519035A (ja) *	2001-12-07	2005-06-30	インターツェル・アクチェンゲゼルシャフト	免疫促進性オリゴデオキシヌクレオチド
ATE485056T1 (de) *	2003-03-24	2010-11-15	Intercell Ag	Verbesserte impfstoffe
CN1822856B (zh) *	2003-07-11	2010-04-28	英特塞尔股份公司	Hcv疫苗
US20090060875A1 (en) *	2004-10-29	2009-03-05	Intercell Ag	HCV Vaccines for Chronic HCV Patients
EP1787660A1 (de) *	2005-11-22	2007-05-23	GBF Gesellschaft für Biotechnologische Forschung mbH	Neue Adjuvanten auf der Basis von Bisacyloxypropylcystein-Konjugaten und ihre Verwendungen in pharmazeuthischen Zusammensetzungen.
SG177141A1 (en) *	2006-12-06	2012-01-30	Novartis Ag	Vaccines including antigen from four strains of influenza virus
WO2009024534A2 (en) *	2007-08-17	2009-02-26	Intercell Ag	Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US20100015171A1 (en) *	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
EP2313116A1 (de) *	2008-08-08	2011-04-27	Intercell AG	Verbesserte bakterielle polysaccharid-polypeptid-konjugat-zusammensetzungen
NZ591768A (en) *	2008-09-18	2012-11-30	Novartis Ag	Vaccine adjuvant combinations
WO2010092479A2 (en)	2009-02-10	2010-08-19	Novartis Ag	Influenza vaccines with reduced amounts of squalene
CN102740882A (zh)	2009-08-27	2012-10-17	诺华有限公司	含有铝、寡核苷酸和聚阳离子的佐剂
CN102695523A (zh)	2009-09-10	2012-09-26	诺华有限公司	针对呼吸道疾病的组合疫苗
GB0917003D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Purification of bacterial vesicles
GB0917002D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Improved shigella blebs
CN102724988B (zh)	2009-09-30	2014-09-10	诺华股份有限公司	脑膜炎球菌fHBP多肽的表达
US8765148B2 (en) *	2010-02-19	2014-07-01	Valneva Austria Gmbh	1C31 nanoparticles
CN102802662A (zh)	2010-03-18	2012-11-28	诺华有限公司	用于脑膜炎球菌血清组b的含佐剂疫苗
CA2803239A1 (en)	2010-06-25	2011-12-29	Novartis Ag	Combinations of meningococcal factor h binding proteins
RU2451373C1 (ru) *	2010-09-10	2012-05-20	Открытое Акционерное Общество "Уральское проектно-конструкторское бюро "Деталь"	Активная фазированная антенная решетка
GB201017519D0 (en)	2010-10-15	2010-12-01	Novartis Vaccines Inst For Global Health S R L	Vaccines
EP2755683B1 (de)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Verfahren zur herstellung von saccharidprotein-glykokonjugaten
WO2014044690A1 (en)	2012-09-18	2014-03-27	Valneva Austria Gmbh	Improved vaccines
US9764027B2 (en)	2012-09-18	2017-09-19	Glaxosmithkline Biologicals Sa	Outer membrane vesicles
US20150220643A1 (en) *	2014-01-31	2015-08-06	International Business Machines Corporation	Scoring properties of social media postings
US10816554B2 (en)	2014-04-04	2020-10-27	The Board Of Trustees Of The Leland Stanford Junior University	Ligand discovery for T cell receptors
EP3393509B1 (de)	2015-12-23	2024-02-28	Valneva SE	Zikavirusreinigung
EP3515483A4 (de)	2016-09-21	2020-12-16	The Governors of the University of Alberta	Immunogene zusammensetzungen des hepatitis-c-virus und verfahren zur verwendung davon
MA46584A (fr) *	2016-10-21	2019-08-28	Modernatx Inc	Vaccin contre le cytomégalovirus humain
CN108314708B (zh) *	2017-01-17	2021-03-05	南京农业大学	一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用
PH12021552736A1 (en)	2019-05-20	2022-07-11	Valneva Se	A subunit vaccine for treatment or prevention of a respiratory tract infection
CN115120713A (zh) *	2021-03-25	2022-09-30	四川大学	氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
JP2024522385A (ja)	2021-04-09	2024-06-19	ヴァルネヴァエスイー	ヒトメタニューモウイルスワクチン

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5683864A (en)	1987-11-18	1997-11-04	Chiron Corporation	Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
ATE346302T1 (de)	1990-08-25	2006-12-15	Bioprocess Pty Ltd	Nicht-a, nicht-b hepatitis virus antigen, und diagnostische verfahren.
WO1993000365A2 (en)	1991-06-24	1993-01-07	Chiron Corporation	Hepatitis c virus (hcv) polypeptides
US6419931B1 (en)	1991-08-26	2002-07-16	Epimmune Inc.	Compositions and methods for eliciting CTL immunity
US6037135A (en)	1992-08-07	2000-03-14	Epimmune Inc.	Methods for making HLA binding peptides and their uses
US5333965A (en)	1992-01-31	1994-08-02	Mailey John W	In situ modular fastening system
CN1118572A (zh)	1993-03-05	1996-03-13	萨依特尔有限公司	Hla-a2.1组合肽及其用途
EP0651807B1 (de)	1993-04-27	2007-09-12	N.V. Innogenetics S.A.	Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
US5709995A (en)	1994-03-17	1998-01-20	The Scripps Research Institute	Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
AU697171B2 (en)	1994-04-08	1998-10-01	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure
WO1995027901A1 (en)	1994-04-11	1995-10-19	Ixsys, Inc.	Class i peptide binding motifs
ATE509102T1 (de)	1994-07-15	2011-05-15	Univ Iowa Res Found	Immunomodulatorische oligonukleotide
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
GB9620795D0 (en)	1996-10-05	1996-11-20	Smithkline Beecham Plc	Vaccines
RS50101B (sr)	1996-02-24	2009-01-22	Boehringer Ingelheim International Gmbh.,	Farmaceutski preparati za imunomodulaciju
ES2241042T3 (es)	1996-10-11	2005-10-16	The Regents Of The University Of California	Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US6562345B1 (en)	1996-11-12	2003-05-13	City Of Hope	Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6413517B1 (en)	1997-01-23	2002-07-02	Epimmune, Inc.	Identification of broadly reactive DR restricted epitopes
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2289741A1 (en)	1997-05-19	1998-11-26	Merck & Co., Inc.	Oligonucleotide adjuvant
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
EP1021239B1 (de)	1997-09-19	2002-11-20	Valtion Teknillinen Tutkimuskeskus	Gasfilter
GB9727262D0 (en) *	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
DE19803453A1 (de)	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
ATE356630T1 (de)	1998-04-03	2007-04-15	Univ Iowa Res Found	Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1077708A1 (de)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
ES2281179T3 (es)	1998-06-09	2007-09-16	Andrea D. Branch	Nuevos peptidos del virus de la hepatitis c y usos de los mismos.
WO2000011186A1 (en)	1998-08-21	2000-03-02	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modified hcv peptide vaccines
DE69935606T9 (de)	1998-10-16	2021-03-11	Glaxosmithkline Biologicals S.A.	Adjuvanzsysteme und impfstoffe
AU1744600A (en)	1998-11-24	2000-06-13	Thomas Jefferson University	Detection of t cell stimulating tumor antigens
WO2000044775A2 (en)	1999-01-27	2000-08-03	Epimmune Inc.	Identification of broadly reactive hla restricted t cell epitopes
DE60014076T2 (de) *	1999-04-19	2005-10-13	Glaxosmithkline Biologicals S.A.	Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
EP1200109A4 (de)	1999-07-19	2005-06-15	Epimmune Inc	Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
GB9921146D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
AT408721B (de)	1999-10-01	2002-02-25	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
WO2001054719A2 (en)	2000-01-31	2001-08-02	Smithkline Beecham Biologicals S.A.	Vaccine for the prophylactic or therapeutic immunization against hiv
EP1272215B1 (de)	2000-04-14	2007-10-10	Intercell AG	Modifizierte peptide enthaltende pharmazeutische präparationen
AU2001281812B2 (en)	2000-06-08	2005-04-07	Valneva Austria Gmbh	Immunostimulatory oligodeoxynucleotides
AT410173B (de)	2000-06-08	2003-02-25	Cistem Biotechnologies Gmbh	Antigene zusammensetzung
US20040170642A1 (en)	2000-08-17	2004-09-02	Jorg Fritiz	Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof
ATE350015T1 (de) *	2000-09-28	2007-01-15	Novartis Vaccines & Diagnostic	Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
WO2002033127A2 (en)	2000-10-17	2002-04-25	Thomas Jefferson University	Method for assessing recoding in vitro and in vivo
AT410635B (de) *	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
JP2004519453A (ja) *	2001-01-05	2004-07-02	インターツェル・アクチェンゲゼルシャフト	ポリカチオン性化合物の用途
WO2002053184A2 (en) *	2001-01-05	2002-07-11	Intercell Ag	Uses for polycationic compounds as vaccine adjuvants
JP4188092B2 (ja)	2001-05-21	2008-11-26	インターツェル・アクチェンゲゼルシャフト	免疫促進性オリゴデオキシ核酸分子
JP2005519035A (ja) *	2001-12-07	2005-06-30	インターツェル・アクチェンゲゼルシャフト	免疫促進性オリゴデオキシヌクレオチド
WO2003073097A2 (en)	2002-02-28	2003-09-04	Intercell Ag	Methods for isolating ligands e.g. t cell epitopes
FR2843115B1 (fr)	2002-08-02	2007-11-09	Commissariat Energie Atomique	Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
EP2402026A3 (de) *	2002-09-13	2012-04-18	Intercell AG	Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden
ATE485056T1 (de) *	2003-03-24	2010-11-15	Intercell Ag	Verbesserte impfstoffe

2004
- 2004-03-22 AT AT04722281T patent/ATE485056T1/de active
- 2004-03-22 AU AU2004224746A patent/AU2004224746B2/en not_active Expired
- 2004-03-22 EP EP04722281A patent/EP1608402B1/de not_active Expired - Lifetime
- 2004-03-22 EP EP10173930.8A patent/EP2345420B1/de not_active Expired - Lifetime
- 2004-03-22 US US10/550,754 patent/US7704514B2/en not_active Expired - Lifetime
- 2004-03-22 JP JP2006504798A patent/JP4676426B2/ja not_active Expired - Lifetime
- 2004-03-22 DE DE602004029657T patent/DE602004029657D1/de not_active Expired - Lifetime
- 2004-03-22 CA CA2517673A patent/CA2517673C/en not_active Expired - Lifetime
- 2004-03-22 ES ES10173930.8T patent/ES2562456T3/es not_active Expired - Lifetime
- 2004-03-22 WO PCT/EP2004/003002 patent/WO2004084938A1/en not_active Ceased
2009
- 2009-06-17 AU AU2009202420A patent/AU2009202420B2/en not_active Expired
2010
- 2010-04-13 US US12/759,318 patent/US8784837B2/en not_active Expired - Lifetime
- 2010-10-22 JP JP2010237719A patent/JP2011042678A/ja not_active Withdrawn
2013
- 2013-01-30 JP JP2013015860A patent/JP5586717B2/ja not_active Expired - Lifetime
2014
- 2014-06-11 US US14/301,539 patent/US20150010595A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2345420B1 (de)	2016-01-06
JP4676426B2 (ja)	2011-04-27
JP5586717B2 (ja)	2014-09-10
EP2345420A1 (de)	2011-07-20
AU2004224746A1 (en)	2004-10-07
JP2013121975A (ja)	2013-06-20
US8784837B2 (en)	2014-07-22
AU2009202420A1 (en)	2009-07-09
CA2517673C (en)	2013-08-13
WO2004084938A1 (en)	2004-10-07
AU2009202420B2 (en)	2012-04-26
US20100297170A1 (en)	2010-11-25
ES2562456T3 (es)	2016-03-04
US7704514B2 (en)	2010-04-27
JP2011042678A (ja)	2011-03-03
AU2004224746B2 (en)	2009-04-23
CA2517673A1 (en)	2004-10-07
EP1608402B1 (de)	2010-10-20
US20150010595A1 (en)	2015-01-08
JP2006521320A (ja)	2006-09-21
US20060263386A1 (en)	2006-11-23
DE602004029657D1 (de)	2010-12-02
EP1608402A1 (de)	2005-12-28

Legal Events

Date

Code

Title

Description

2011-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1608402

Country of ref document: EP

Publication	Publication Date	Title
ATE485056T1 (de)	2010-11-15	Verbesserte impfstoffe
WO2004030608A3 (en)	2005-03-10	Nanoemulsion vaccines
ATE451119T1 (de)	2009-12-15	Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1112749T1 (el)	2016-02-10	Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
EP1594536A4 (de)	2006-09-06	Adjuvante influenza-vakzine
MXPA05009580A (es)	2005-10-19	Vacuna contra el virus de la influenza.
DE60226911D1 (de)	2008-07-10	Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
DE60012711D1 (de)	2004-09-09	Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
ATE503493T1 (de)	2011-04-15	Influenza vakzinzusammensetzungen zur intradermaler verabreichung
DE60121136D1 (de)	2006-08-10	Proteasom-influenzavirus-impfstoffzusammensetzung
CY1112879T1 (el)	2016-04-13	Συνθεση εμβολιου
WO2003080114A3 (en)	2003-11-06	Imidazoquinoline adjuvants for vaccines
CY1112014T1 (el)	2015-11-04	Συνθεσεις αντιβακτηριακων εμβολιων
ATE270707T1 (de)	2004-07-15	Entepneumovirus und entsprechendes impfstoff
WO2004045529A3 (en)	2004-08-26	West nile virus vaccine
ATE511855T1 (de)	2011-06-15	Adjuvansformulierung zur scheimhaut-applikation
ATE458496T1 (de)	2010-03-15	Hiv-vakzine und anwendungsverfahren
IL158428A0 (en)	2004-05-12	Vaccine composition comprising at least one hiv virus antigen
WO2005028496A3 (en)	2005-10-06	Vaccine for treatment and prevention of herpes simplex virus infection
AU2001292610A1 (en)	2002-03-22	Genetically engineered co-expression dna vaccines, construction methods and uses thereof
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
DK1112747T3 (da)	2004-10-25	Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
CY1107560T1 (el)	2013-03-13	Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
PL1949913T3 (pl)	2010-10-29	Immunostymulująca kombinacja do profilaktyki i leczenia wirusowego zapalenia wątroby typu c
ATE505482T1 (de)	2011-04-15	Impfstoff gegen infektiöses lachsanämievirus